SpringWorks Shares Rise on FDA Approval for Tumor Treatment
By Dean Seal
Shares of SpringWorks were higher after the company received regulatory approval for its treatment of desmoid tumors.
The stock was up 11% at $23.01 in premarket trading. Shares had fallen 20% year-to-date when the market closed Monday.
The Stamford, Conn.-based biopharmaceutical company said after the bell on Monday that the U.S. Food and Drug Administration has approved Ogsiveo for adults with progressing desmoid tumors who require systemic treatment.
SpringWorks said Ogsiveo was the first FDA-approved therapy for patients with desmoid tumors.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 28, 2023 07:38 ET (12:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst